Company Filing History:
Years Active: 2023-2025
Title: Innovations by Inventor Xiaojie Yao in Cytomegalovirus Research
Introduction
Xiaojie Yao is an accomplished inventor based in East Lyme, Connecticut, known for his significant contributions to the field of virology. With two patents to his name, he has made notable advancements in the understanding of human cytomegalovirus (HCMV) and its glycoprotein B (gB), which plays a critical role in the virus's lifecycle.
Latest Patents
Yao's latest patents focus on innovative mutants of the wild-type cytomegalovirus glycoprotein B. The first patent outlines mutants that include at least two introduced amino acid mutations relative to the wild-type HCMV gB protein. It discusses compositions featuring these mutants and their uses, emphasizing that some of the mutants are stabilized in a conformation alternative to the gB postfusion conformation. The second patent similarly addresses polypeptides and antigens related to HCMV, incorporating at least one introduced amino acid mutation. This patent also highlights compositions and the potential applications of these polypeptides, again noting stabilization in an alternative conformation.
Career Highlights
Xiaojie Yao is currently affiliated with Pfizer Corporation, a leading biopharmaceutical company. His work at Pfizer not only showcases his expertise but also aligns with the company's commitment to advancing medical research and developing therapeutic solutions for various viral infections, including cytomegalovirus.
Collaborations
Throughout his career, Yao has collaborated with talented professionals, including coworkers Yuhang Liu and Ye Che. These collaborations highlight the importance of teamwork in scientific research and the innovative processes involved in tackling complex biological challenges.
Conclusion
Xiaojie Yao's contributions to the field of cytomegalovirus research through his patented innovations have the potential to enhance understanding and treatment of viral infections. As he continues his work at Pfizer Corporation, the scientific community anticipates further advancements that may stem from his ongoing research endeavors.